Clin Osteol 2024; 29(3): 77-79

Kardiovaskulární riziko při léčbě romosozumabemComments

Vrablík Michal
Centrum preventivní kardiologie, III. interní klinika - endokrinologie a metabolismu 1. LF UK a VFN v Praze

Published: December 11, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrablík M. Kardiovaskulární riziko při léčbě romosozumabem. Clinical Osteology. 2024;29(3):77-79.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Szekanecz Z, Raterman HG, Pethő Z et al. Common mechanisms and holistic care in atherosclerosis and osteoporosis. Arthritis Res Ther 2019; 21(1): 15. Dostupné z DOI: <http://dx.doi.org/10.1186/s13075-018-1805-7>. Go to original source...
    2. Laroche M, Pécourneau V, Blain H et al. Osteoporosis and ischemic cardiovascular disease. Joint Bone Spine 2017; 84(4): 427-432. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jbspin.2016.09.022>. Go to original source...
    3. Kroupova K, Palicka V, Rosa J. Monoclonal antibodies for treatment of osteoporosis. Drugs Today (Barc) 2023; 59(3): 195-204. Dostupné z DOI: <http://dx.doi.org/10.1358/dot.2023.59.3.3453905>. Go to original source...
    4. Saag KG, Petersen J, Brandi ML et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017; 377(15): 1417-1427. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1708322>. Go to original source...
    5. Cosman F, Crittenden DB, Adachi JD et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 2016; 375(16): 1532-1543. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1607948>. Go to original source...
    6. Reid IR. What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab? Expert Opin Drug Saf 2022; 21(12): 1441-1443. Dostupné z DOI: <https://doi.org/10.1080/14740338.2022.2160445>. Go to original source...
    7. Di Monaco M, Castiglioni C, Bardesono F. Letter to the editor: consideration on: 'What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?' by Reid IR. Expert Opin Drug Saf 2023; 22(1): 103-104. Dostupné z DOI: <https://doi.org/10.1080/14740338.2023.2173737>. Go to original source...
    8. Vrablík M, Cífková R, Tuka V et al. Doporučený postup Evropské kardiologické společnosti pro prevenci kardiovaskulárních onemocnění v klinické praxi 2021. Souhrn dokumentu připravený Českou kardiologickou společností. Cor Vasa 2022; 64(2): 165-211. Dostupné z DOI: <http://dx.doi.org/10.33678/cor.2022.035>. Go to original source...
    9. EVENITY. SPC. Dostupné z WWW: <https://www.ema.europa.eu/cs/documents/product-information/evenity-epar-product-information_cs.pdf>.
    10. EVENITY®prescribing information, Amgen KK, Tokyo, Japan.
    11. EVENITY™ (romosozumab), medication guide, Amgen Korea Limited, Seoul, South Korea. Dostupné z WWW: <https://www.amgen.co.kr/en/products/evenity>.
    12. EVENITY™ (romosozumab-aqqg) prescribing information, Amgen Inc, Thousand Oaks, CA. Dostupné z WWW: <https://www.blueshieldca.com/content/dam/bsca/en/provider/docs/2023/November/PRV_MP_Romosozumabaqqg_Evenity.pdf>.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.